BlackRock Institutional Trust Company N.A. boosted its position in shares of Radius Health Inc. (NASDAQ:RDUS) by 0.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 807,600 shares of the biopharmaceutical company’s stock after buying an additional 3,792 shares during the period. BlackRock Institutional Trust Company N.A. owned about 1.88% of Radius Health worth $25,391,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. Dimensional Fund Advisors LP purchased a new stake in Radius Health during the fourth quarter worth about $1,362,000. Nationwide Fund Advisors increased its stake in Radius Health by 1.8% in the fourth quarter. Nationwide Fund Advisors now owns 24,238 shares of the biopharmaceutical company’s stock worth $1,492,000 after buying an additional 437 shares during the period. Verde Servicos Internacionais S.A. purchased a new stake in Radius Health during the first quarter worth about $1,535,000. Teachers Advisors Inc. increased its stake in Radius Health by 1.9% in the first quarter. Teachers Advisors Inc. now owns 50,805 shares of the biopharmaceutical company’s stock worth $1,597,000 after buying an additional 926 shares during the period. Finally, Rhumbline Advisers increased its stake in Radius Health by 12.8% in the fourth quarter. Rhumbline Advisers now owns 31,671 shares of the biopharmaceutical company’s stock worth $1,949,000 after buying an additional 3,585 shares during the period.
Shares of Radius Health Inc. (NASDAQ:RDUS) traded down 1.57% on Thursday, hitting $45.80. The company’s stock had a trading volume of 368,829 shares. The stock’s 50 day moving average price is $39.05 and its 200 day moving average price is $35.20. The stock’s market capitalization is $1.97 billion. Radius Health Inc. has a 52 week low of $24.75 and a 52 week high of $79.90.
A number of equities research analysts have issued reports on the company. HC Wainwright assumed coverage on Radius Health in a research report on Monday, May 23rd. They set a “buy” rating and a $55.00 price target for the company. Cantor Fitzgerald reissued a “buy” rating and set a $70.00 price target on shares of Radius Health in a research report on Thursday, March 31st. Cowen and Company began coverage on Radius Health in a research note on Friday, May 6th. They set an “outperform” rating on the stock. Zacks Investment Research upgraded Radius Health from a “sell” rating to a “hold” rating in a research note on Monday, May 2nd. Finally, Canaccord Genuity restated a “buy” rating on shares of Radius Health in a research note on Monday, April 4th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Radius Health currently has a consensus rating of “Buy” and an average price target of $70.07.
Radius Health, Inc is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, oncology and endocrine diseases. The Company’s lead product candidate is the investigational drug abaloparatide for subcutaneous injection (abaloparatide-SC), which has completed Phase III development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis.
